Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Acquisitions (2017 - 2018)

Ptc Therapeutics (PTCT) has 1 years of Acquisitions data on record, last reported at -$76.4 million in Q3 2017.

  • For Q3 2017, Acquisitions changed N/A year-over-year to -$76.4 million; the TTM value through Dec 2019 reached -$76.4 million, changed 0.0%, while the annual FY2018 figure was $48.9 million, N/A changed from the prior year.
  • Acquisitions reached -$76.4 million in Q3 2017 per PTCT's latest filing.
  • Across five years, Acquisitions topped out at -$76.4 million in Q3 2017 and bottomed at -$76.4 million in Q3 2017.